Oral therapy for multiple sclerosis--sea change or incremental step?
- PMID: 20089958
- DOI: 10.1056/NEJMe0912019
Oral therapy for multiple sclerosis--sea change or incremental step?
Comment on
-
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.N Engl J Med. 2010 Feb 4;362(5):387-401. doi: 10.1056/NEJMoa0909494. Epub 2010 Jan 20. N Engl J Med. 2010. PMID: 20089952 Clinical Trial.
-
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.N Engl J Med. 2010 Feb 4;362(5):402-15. doi: 10.1056/NEJMoa0907839. Epub 2010 Jan 20. N Engl J Med. 2010. PMID: 20089954 Clinical Trial.
-
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.N Engl J Med. 2010 Feb 4;362(5):416-26. doi: 10.1056/NEJMoa0902533. Epub 2010 Jan 20. N Engl J Med. 2010. PMID: 20089960 Clinical Trial.
Similar articles
-
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.N Engl J Med. 2010 Feb 4;362(5):402-15. doi: 10.1056/NEJMoa0907839. Epub 2010 Jan 20. N Engl J Med. 2010. PMID: 20089954 Clinical Trial.
-
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.N Engl J Med. 2010 Feb 4;362(5):387-401. doi: 10.1056/NEJMoa0909494. Epub 2010 Jan 20. N Engl J Med. 2010. PMID: 20089952 Clinical Trial.
-
Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence?Neurology. 2012 Mar 20;78(12):928-30. doi: 10.1212/WNL.0b013e31824c46ad. Epub 2012 Mar 7. Neurology. 2012. PMID: 22402856 No abstract available.
-
Fingolimod for the treatment of relapsing multiple sclerosis.Expert Rev Neurother. 2011 Feb;11(2):165-83. doi: 10.1586/ern.10.193. Epub 2010 Dec 16. Expert Rev Neurother. 2011. PMID: 21158700 Review.
-
Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.Drug Des Devel Ther. 2010 Jul 21;4:117-26. doi: 10.2147/dddt.s6627. Drug Des Devel Ther. 2010. PMID: 20689698 Free PMC article. Review.
Cited by
-
Interferon-β-1b: a review of its use in multiple sclerosis.CNS Drugs. 2011 Jan;25(1):67-88. doi: 10.2165/11206430-000000000-00000. CNS Drugs. 2011. PMID: 21128695 Review.
-
Expression of leukotriene B4 receptor 1 defines functionally distinct DCs that control allergic skin inflammation.Cell Mol Immunol. 2021 Jun;18(6):1437-1449. doi: 10.1038/s41423-020-00559-7. Epub 2020 Oct 9. Cell Mol Immunol. 2021. PMID: 33037399 Free PMC article.
-
New hope for multiple sclerosis patients.ACS Chem Neurosci. 2013 Mar 20;4(3):368. doi: 10.1021/cn400059g. ACS Chem Neurosci. 2013. PMID: 23509970 Free PMC article. No abstract available.
-
Endogenous migration modulators as parent compounds for the development of novel cardiovascular and anti-inflammatory drugs.Br J Pharmacol. 2012 Apr;165(7):2044-58. doi: 10.1111/j.1476-5381.2011.01762.x. Br J Pharmacol. 2012. PMID: 22035209 Free PMC article. Review.
-
Fingolimod (FTY720): First approved oral therapy for multiple sclerosis.J Pharmacol Pharmacother. 2011 Jan;2(1):49-51. doi: 10.4103/0976-500X.77118. J Pharmacol Pharmacother. 2011. PMID: 21701650 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources